Fifteen percent of all BC overexpresses HER2 and approximately 50% of these are also classified as hormone receptor positive (HR+), which confers substantial differences in biology and clinical outcome from HR+/HER2- disease. The gene discussed is ERBB2; the disease is breast cancer.